Identification of degradation products of cilostazol drug substance

Magdalena Kossykowska ,  Marta Zezula ,  Joanna Zagrodzka ,  Katarzyna Badowska-Rosłonek 

Pharmaceutical Research Institute (IF), Rydygiera 8, Warszawa 01-793, Poland

Abstract

Cilostazol, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, is used to improve the symptoms of blood flow problem in the legs (intermittent claudication). Cilostazol can increase blood flow and the amount of oxygen that gets to the muscles. It works by preventing platelets blood from sticking together and by widening blood vessels in the legs. This helps the blood to move more easily and increases blood flow [1].

The crude cilostazol obtained using the synthetic route developed in PRI contains four main impurities. The impurities were identified. Additionally, stress testing studies were performed to determine the stability of the drug substance under different conditions (neutral, acidic, basic hydrolysis and oxidative degradation) and identify the main degradation products. Attempts to make structural assignment of these compounds by HPLC-MS-MS was the main assumption of this work. Based on the HPLC-MS-MS analyses the potential structures of the degradation products were proposed.

Acknowledgement:
The study was supported by European Union under European Regional Development Fund No. UDA-POiG.01.03.01-14-062/09-00 “Innovative technologies of cardiovascular medicines of special therapeutic and social importance”.

References:
[1] Note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease. Committee for proprietary Medical Products. The European Agency for the Evaluation of Medical Products. http://www.emea.eu.

 

Related papers
  1. Hplc study of Cilostazol tablets: assay and release profile determination
  2. Determination of organic volatile impurities in Nepafenac by GC method
  3. Application of the new data processing method for photodiode array detector in the analysis of drug substances
  4. Validation of HPLC methods for analyzing the chemical purity of cilostazol
  5. An application of accelerator mass spectrometry (AMS) in pediatric clinical studies. Paracetamol, midazolam and spironolactone radiosynthesis and certification.
  6. Comparative permeation studies of tacalcitol through the human skin from brand product versus generic product
  7. Development and validation of the HPLC-UV method for impurities determination in duloxetine hydrochloride
  8. HPLC methods for in–process control and chemical purity determination of olopatadine
  9. Development and validation of HPLC method. Review of selected cases.
  10. HPLC method for determination of the enantiomeric purity of a new ω chain aldehyde synthon used in the synthesis of travoprost
  11. Physicochemical characterization of sunitinib and its impurities
  12. Synthesis and biological evaluation of new amino acid and dipeptide derivatives of neocryptolepine as anticancer agents. 
  13. Analytical control of synthesis and determination of BR-S by HPLC
  14. Optimization of BR-8 synthesis
  15. HPLC method as an analitycal control of synthesis and determination of TZ-S
  16. The synthesis of ezetimibe with high stereochemical purity
  17. Validation of a HPLC method for LI-S analysis
  18. HPLC Methods for Stress Testing of ZL-S Drug Substances
  19. Zolmitriptan synthesis and in-process control by HPLC methods
  20. The cytotoxic activity of glycosides of indolo[2,3-b]quinoline derivatives.
  21. HPLC as a method for analytical control of synthesis and determination of tolterodine (TD-S)
  22. Development of HPLC and GC methods for analysis of Zolmitriptan of pharmaceutical purity
  23. Optimization of AR-3 synthesis
  24. CHARACTERIZATION OF ARIPIPRAZOLE SOLVATE WITH ETHANOL AND POLYMORPHIC FORMS PRODUCED DURING ITS HEATING
  25. HPLC SEPARATION AND DETERMINATION OF ZIPRASIDONE
  26. SYNTHESIS OF GLIMEPIRIDE - CRYSTAL STRUCTURE ANALYSIS STEP BY STEP
  27. HPLC AS A METHOD FOR ANALYTICAL CONTROL OF SYNTHESIS AND DETERMINATION OF PRAMIPEXOLE
  28. THE CYTOTOXIC GLYCOSIDES OF INDOLO[2,3-B]QUINOLINE DERIVATIVES. IN VITRO AND IN VIVO STUDIES
  29. 1H AND 13C NMR DATA FOR INDOLO[2,3-b]QUINOLINES - AMINOGLYCOSIDE HYBRIDS, A NOVEL POTENT ANTICANCER DRUG FAMILY .
  30. NEW SYNTHESIS OF 11-(1-PIPERAZINYL)- DIBENZO[b,f][1,4]THIAZEPINE, A CRUCIAL INTERMEDIATE IN QUETIAPINE PRODUCTION.

Presentation: Poster at IX Multidyscyplinarna Konferencja Nauki o Leku, by Magdalena Kossykowska
See On-line Journal of IX Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2014-03-13 08:45
Revised:   2014-05-02 11:48